

# Recombinant Mouse Erythropoietin/EPO, Tag Free

#### Information

Accession #	Q0VED9
Alternate Names	ECYT5; EP; EPO; epoetin; Erythropoietin; MGC138142; MVCD2
Source	Human embryonic kidney cell, HEK293-derived mouse Erythropoietin/EPO protein
Protein sequence	Ala27-Arg192
M.Wt	18.6 kDa
Appearance	Solution protein
Stability & Storage	Avoid repeated freeze-thaw cycles. It is recommended that hat the protein be aliquoted for optimal storage 12 months from date of receipt, -20 to -70°C as supplied.
Concentration	0. 2 mg/mL
Formulation	Dissolved in sterile PBS buffer.
Reconstitution	We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. This solution can be diluted into other aqueous buffers.
<b>Biological Activity</b>	The EC50 for this effect is 0.1-0.4 ng/mL. Measured in a cell proliferation assay using TF-1 human erythroleukemic cells.
Shipping Condition	Shipping with dry ice.
Handling	Centrifuge the vial prior to opening.
Usage	For Research Use Only! Not to be used in humans.
cilion	Sector Sector

## **Quality Control**

Purity	> 95%, determined by SDS-PAGE.
Endotoxin	<0.010 EU per 1 ug of the protein by the LAL method.

## Description

Erythropoietin (EPO) is a 34 kDa glycoprotein hormone in the type I cytokine family and is related to thrombopoietin <sup>[1]</sup>. Its three N-glycosylation sites, four alpha helices, and N- to C-terminal disulfide bond are conserved across species <sup>[2, 3]</sup>. Glycosylation of EPO is required for biological activities in vivo <sup>[4]</sup>. Mature mouse EPO shares 95% amino acid sequence identity with rat EPO and 73%-82% with bovine, canine, equine, feline, human, ovine, and porcine EPO. Epo is primarily produced in the kidney by a population of fibroblast-like cortical interstitial cells adjacent to the proximal tubules <sup>[5]</sup>. It is also produced in much lower, but functionally significant amounts by fetal hepatocytes and in adult liver and brain <sup>[6-8]</sup>. EPO promotes erythrocyte formation by preventing the apoptosis of early erythroid precursors which express the (EPO receptor (EPOR))<sup>[8, 9]</sup>. EPO R has also been described in brain, retina,

heart, skeletal muscle, kidney, endothelial cells, and a variety of tumor cells <sup>[7,8,10,11]</sup>. Ligand induced dimerization of EPOR triggers JAK2-mediated signaling pathways followed by receptor/ligand endocytosis and degradation [<sup>1,12]</sup>. Rapid regulation of circulating EPO allows tight control of erythrocyte production and hemoglobin concentrations. Anemia or other causes of low tissue oxygen tension induce EPO production by stabilizing the hypoxia-induceable transcription factors HIF-1 alpha and HIF-2 alpha <sup>[1,6]</sup>. EPO additionally plays a tissue-protective role in ischemia by blocking apoptosis and inducing angiogenesis <sup>[7,8,13]</sup>.

#### Reference

- [1]. Koury, M. J. (2005) Exp. Hematol. 33:1263.
- [2]. Shoemaker, C.B. and L.D. Mitsock (1986) Mol. Cell. Biol 6:849.
- [3]. Wen, D. et al. (1993) Blood 82:1507.
- [4]. Tsuda E. et al. (1990) Eur. J. Biochem. 188:405.
- [5]. Lacombe, C. et al. (1988) J. Clin. Invest. 81:620.
- [6]. Eckardt, K. U. and A. Kurtz (2005) Eur. J. Clin. Invest. 35 Suppl. 3:13.
- [7]. Sharples, E. J. et al. (2006) Curr. Opin. Pharmacol. 6:184.
- [8]. Rossert, J. and K. Eckardt (2005) Nephrol. Dial. Transplant 20:1025.
- [9]. Koury, M.J. and M.C. Bondurant (1990) Science 248:378.
- [10]. Acs, G. et al. (2001) Cancer Res. 61:3561.
- [11]. Hardee, M.E. et al. (2006) Clin. Cancer Res.
- [12]:332. 12. Verdier, F. et al. (2000) J. Biol. Chem. 275:18375.
- [13]. Kertesz, N. et al. (2004) Dev. Biol. 276:101

APEABIC STREET





e research topoche un



7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com